Systematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providers.

Introduction: Several current therapies for autoimmune diseases do not provide sustained remission. Therapies that focus on the restoration of homeostasis within the immune system (i.e., immune resolution) could overcome the limitations of current therapies and provide more durable remission. However, there is no established consensus on appropriate clinical trial designs and endpoints to evaluate such therapies. Therefore, we conducted a systematic literature review (SLR) focusing on five index diseases (asthma, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus [SLE], and ulcerative colitis) to explore published literature on 1) expert opinion on immune-resolution outcomes that should be measured in clinical trials; and 2) quantification of immune resolution in previous clinical trials.
Methods: The SLR was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Embase and MEDLINE databases were systematically searched (2013-2023) for published English language articles. Conference proceedings (2020-2022) from American Academy of Dermatology, American College of Rheumatology, Digestive Disease Week, European Alliance of Associations for Rheumatology, and European Academy of Dermatology and Venereology were searched to include relevant abstracts. The study protocol was registered in PROSPERO (CRD42023406489).
Results: The SLR included 26 publications on 20 trials and 12 expert opinions. Expert opinions generally lacked specific recommendations on the assessment of immune resolution in clinical trials and instead suggested targets or biomarkers for future therapies. The targets included thymic stromal lymphopoietin ( TSLP ) in asthma; T helper (Th)2 and Th22 cells and their respective cytokines (interleukin [IL]-4R and IL-22) in atopic dermatitis; inhibitory/regulatory molecules involved in T-cell modulation, and protein tyrosine phosphatase, non-receptor type 22 ( PTPN22 ) in rheumatoid arthritis; low-dose IL-2 therapy in SLE; and pro-resolution mediators in ulcerative colitis and asthma. In the interventional studies, direct biomarker assessments of immune resolution were the number/proportion of regulatory T-cells (Treg) and the ratio Th17/Treg in SLE and rheumatoid arthritis; the number of T follicular helper cells (Tfh), Th1, Th2, Th17, and Th22 in atopic dermatitis, rheumatoid arthritis, and SLE; and mucosal proinflammatory gene signatures (tumor necrosis factor [ TNF ], interleukin 1 alpha [ IL1A ], regenerating family member 1 alpha [ REG1A ], IL8 , interleukin 1 beta [ IL1B ], and leukocyte immunoglobulin-like receptors A [ LILRA ]) in ulcerative colitis. Several studies reported a statistically significant relationship between clinical remission and immune-resolution biomarkers, suggesting a link between T-cell homeostasis, cytokine production, and disease activity in autoimmune diseases.
Discussion: Existing literature does not offer clear guidance on the evaluation of immune resolution in interventional studies. Further research and consensus are needed to assess a treatment's ability to induce long-term remission or low disease activity.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023406489, identifier CRD42023406489.
Competing Interests: PK: Employment and stockholder, Eli Lilly and Company. LL: Employment, Evidera Inc. BM: Employment and stockholder, Eli Lilly and Company. II: Employment, Evidera Inc. RB: Employment and stockholder, Eli Lilly and Company. AC: Employment and stockholder, Eli Lilly and Company. JP: Employment and stockholder, Eli Lilly and Company. AN: Former employee and stockholder, Eli Lilly and Company. Work related to the systematic literature review was performed during his tenure at Eli Lilly and Company. The authors declare that this study received funding from Eli Lilly and Company, United States. The funder had the following involvement in the study: Funding for the study and all support for the manuscript.
(Copyright © 2024 Klekotka, Lavoie, Mitchell, Iheanacho, Burge, Cohee, Puckett and Nirula.)